Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial
Haal S, Guman MSS, Boerlage TCC, Acherman YIZ, de Brauw LM, Bruin S et al.
Lancet Gastroenterol Hepatol 2021; 6: 993-1001.
In this trial that included 985 patients, ursodeoxycholic acid therapy did not reduce the risk of symptomatic gallstone disease: relative risk 0.67, 95 per cent confidence interval 0.43 to 1.04, P=0.071. The risk was reduced in patients without gallstones at baseline, compared to those who did.
Comment: It seems like treatment should be offered selectively.
1 January 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.